Sydney Chen, President
Dr. Chen is currently Director of Quality Control & Bioanalytics at Solstice Neurosciences. Her seventeen plus years of biopharmaceutical industry experience encompassed discovery and development of diagnostic markers and therapeutic drugs, assay development as well as quality management. In her current role, Dr. Chen is responsible for assay analytical development and product quality control of company’s protein drug. She is also the CMC lead for regulatory correspondences for product’s worldwide commercial market. Prior joining Solstice, she has made significant contributions at various roles for Telik, diaDexus, GeneMed and Bristol Myers Squibb. She received her doctoral degree in Biochemistry and Molecular Biology from Rutgers, State University of New Jersey. Being a long time CBA volunteer, Dr. Chen has served in various capacities in the past, including two terms of vice president in 1999 and 2009.
Patty Kiang, Vice-President
Dr. Patty Kiang has a broad experience in Biotech and Pharmaceutical industry with leadership, beginning from a bench chemist, quality control to product development. She has been a technical director, CMC leader and Sales /Marketing director in the pharmaceutical/biotech industry working for many companies including Genentech, Schering Plough and West Pharmaceutical. Under her leadership, she and her team has successfully filed and received FDA approval of several products (liquid Interferon, PEG-Interferon, Growth Hormone and many small molecule drug products). Currently she is the head of Business Development and Account Director for Catalent Pharma Solutions. She covers most of the Sales and Marketing of Analytical and Biotech Service s to Biotech and Pharmaceutical companies in the west coast of USA all the way up to British Columbia , Canada plus Asia Pacific and Australia territory.
Yongliang Zhou, Vice-President
Dr. Julie Yang, Public Relations
Julie has a Ph. D, and is a Registered Patent Agent. Currently, she is a Senior Director of IP at Limerick BioPharma, Inc., taking care of IP, contracts and related matters for the company. Prior to Limerick, she was responsible for the IP portfolio of Genelabs Technologies, Inc. Before moving to the Bay Area, she worked in biotech R&D and management around Boston area. She would like to contribute to the activities and promotion of the CBA, as well as to the information exchange between CBA members and other professional organizations.
Cheng-chi Chao, Venue Coordinator
Dr. Chao holds Ph.D. degree in Immunology from University of Iowa and B.S. from National Chung-Hsiung University, Taiwan. Dr. Chao was a postdoctoral fellow in the Department of Microbiology and Immunology at Stanford University. After finishing postdoctoral training at Stanford, he joined Systemix (a Novartis company) as a scientist to study transplantation and cancer immunology for novel drug targets. Thereafter, he joined Nuvelo (formerly Hyseq) as a senior scientist/project leader. His works involved in selection and validation of drug lead and being responsible for animal modeling and in vivo studies. Prior to joining DNAX, he returned to Taiwan as a visiting scientist at Genome Research Center, Academia Sinica in Taipei. He is currently a senior scientist in Schering-Plough Biopharma (formerly DNAX research institute). He is involved in the pre-clinical drug validation and implementation of animal models for human diseases. Dr. Chao has been CBA Vice President in 2007 and 2008.
Michelle Chen, Community Relationship
Dr. Michelle Chen has many years of experience in the pharmaceutical, diagnostics and biotech industries, ranging from business development, strategic marketing, product development & commercialization to drug discovery & development R&D. She has Ph.D. in Biochemistry from the University of Washington and received post-graduate training in Bioinformatics at Stanford University. Currently she is a director of business development at Ventana Medical Systems, a member of the Roche Group.
Jin-Pian Diao, Program
Jeng Her, Program
Dr. Jeng Her started his career as a co-founder of KaloBios Pharmaceuticals, Inc., a therapeutic antibody company which has raised over $76 mil in private rounds since its inception in 2001. The protein-protein interaction selection system, the antibody Humaneering™ and the antibody affinity maturation technologies that he co-invented with Dr. Robert Balint and other scientists there have led to filing of 18 patents in US and worldwide, and eventually become the technology cornerstones for a pipeline of several antibody drugs in various stages of clinical development for inflammatory, oncology and infectious diseases. In addition to KaloBios, he is also a founding scientist and VP of R&D at Multispan, Inc., a company dedicated to developing GPCR-related specialty reagents and providing superior services for cell-based drug profiling, based on a mammalian expression system developed by him and others.
Ta-Kai Li, Secretary
Dr. Li received his Ph.D. Degree in Biochemistry from University of Maryland School of Medicine and B.S. Degree in Chemistry from Tamkang University, Taiwan. His postdoctoral training was to study T cell activation pathways at Dana-Farber Cancer Institute/Harvard Medical School and National Institutes of Health. After completing postdoctoral training, Dr. Li came to Bay Area to work as a research scientist in biopharmaceutical industry, and he gained extensive experience with small molecules in drug screening, assay development, and mechanistic study. Later, Dr. Li joined Stanford University for research on human hepatitis C virus (HCV) and avian influenza (H5N1) virus. In Stanford, Dr. Li generated a panel of human monoclonal antibodies exhibiting potent neutralization of HCV and H5N1 virus infectivity. Dr. Li’s has more than fifteen year experience in research encompassed mall molecules and antibodies. In addition, he has strong interest in clinical development of drugs, biologics, and medical devices. Dr. Li holds Certificate in Clinical Trials Design and Management from the University of California Extension, Santa Cruz. At present time, Dr. Li works in the field of drug safety involving postmarketing pharmacovigilance.
Frank Lin, Web Developer & Community Relationship
Mr. Frank Lin is the Regional Marketing Director in US and General Manager in Asia Pacific of Matchbin, Inc, a Web 2.0 monetizing Content Management System (CMS) provider for newspaper/radio station/magazine industry. He was a Sales Operation / Marketing Specialist at VeriSilicon, a Fabless Semiconductor company. Mr. Lin grew up with family business in pharmaceuticals and is interested in building network in biotech industry. Mr. Lin received his B.A. degree in Electrical and Computer Engineering from Purdue University. Mr. Lin is currently pursuing MBA degree at Santa Clara University.
Cindy Liu, Membership
Ms. Liu has over 10 years of working experience in academic, biotech and pharmaceutical. She has worked in research, development, and quality. Her past experience includes research work at University of Maryland and UCSF, assay development for Bionetics, and technical management as well quality assurance for SynPep. Currently she is working in product quality control at Solstice Neurosciences. Cindy received her Master degree of Molecular Biology from University of Maryland. Cindy has been a CBA member for more than 10 years and has volunteered herself in many CBA events in past years. For leisure, she likes photography, gardening and enjoys spending time with her two sons.
Andrew Teng, Program
Currently a Managing Director at Ecos Lab Co. Mr. Teng has more than 16 years of general management experience in the fields of semiconductor and Bio Science. His broad background includes P&L, operational, BD, product development, marketing, IP protection and M&A. Prior to joining Ecos Lab, Mr. Teng held a senior positions with Encepho Pharmaceutical as V.P. of Business Development. Mr. Teng has extensive international experience having had direct responsibility for business development and strategic planning in Greater China. Mr. Teng has a B.S. degree from San Jose State University.
Katherine Wang, Treasurer
Katherine Wang got her B.S. degree in Optics from Shandong University, Ph.D. in Physics from Syracuse University (Syracuse, NY). She worked as research scientist in Neurodegenerative Diseases Center of University of Virginia. She has years of Hands-on experiences in optical engineering, DNA sequencing, protein purification, drug-protein interactions and cell culture. Professionally trained as physicist, later discovered that her real interest is in clinical data analysis. Now she works as certified advanced SAS programmer in the field of clinical trials in The Business Bridge, a Bio-IT company focusing on meeting the needs of data management of Bio-Pharmaceutical and medical device industries. Katherine has been a volunteer of CBA in past year as an assistant treasurer and a member of CBA web master team. Her diligent work and enthusiasm has been well recognized. She grew up in Wuhan, China and enjoys reading, writing, walking in nature and Scottish Country Dancing.
Peiwen Yu, Publication
Peiwen received her Ph.D. in Immunology/Pathobiological Sciences from the School of Veterinary Medicine University of Wisconsin-Madison, and her BS and MS in Animal Science form National Taiwan University. She has over 20 years of experience in biopharmaceutical industry and research, focusing on drug discovery and development in oncology and inflammation/immunology. She is currently Senior Director of Molecular and Cellular Pharmacology with Exelixis, Inc. since 2001; manages a team of 25 staffs; established and leads the Cell facility, Core assay team and Blood biomarker core; coordinates clinical and discovery research programs. Prior to joining Exelixis, she worked at Rigel, Inc. for 4 years after her post-doctoral research fellowships at Hoffman-La Roche. She is a member of ASH, AAI, and CABS. Recently she jointed the board of TFGHAA-NC and leads the publication group.
Yeping Zhao, Program
Dr. Zhao is working currently as a director of DMPK at Limerick Biopharma. Before he joined Limerick, he was a principal research scientist in DMPK at Roche Pharmaceuticals. Yeping was working as a director of DMPK at Galileo Pharmaceuticals, and associate director of DMPK at Exelixis before working at Roche. Yeping has also worked with Corixa and Sugen as a scientist for years. Yeping started his professional career as an assistant professor of Biochemical Engineering at Tsinghua University (Beijing, China). Yeping has been a reviewer of NSF and the journal of pharmaceutical and biomedical analysis since 1997. He has been a member of advisory council at San Jose Biocenter since 2008. He also serviced Intel International Science and Technology Fair as a judge in 2001 and 2009. Yeping has more than thirty publications as the first author. Yeping was granted "2008 Excellence in Sciences Award" from the American Society for Small Molecule Science and Amgen. Yeping received his master degree from Long Island University (New York) and his Ph.D. degree in Bioanalytical and Pharmaceutical Chemistry from the University of Kansas. He had his post-doctoral training in Biopharmaceutical Sciences at University of California San Francisco.
Sun-Hoffman Lin, Patent Attoney
Dr. Sun-Hoffman currently is a consultant and also serves as Biotechnology Industry Organization’s (BIO) Chief Advisor for Asia. She was President of Chinese Biopharmaceutical Association (CBA) from 2008-2009. She successfully lead the organization to hold its annual conference in Shanghai, in May 2008, Dr. Sun-Hoffman is also active in the area of green technology. In March 2009, she was appointed as Vice President of Public Relation and General Secretary of the Board at US-China Green Energy Council founded in Bay Area in 2008. Dr. Sun-Hoffman has been in the patent field for more than 10 years and was a USPTO patent examiner. She has more than 10 year of biotech research experience including working at NIH. In addition, she also drafted and negotiated various licenses for biotech companies. Dr. Sun –Hoffman served as a Sr. Patent Attorney at Life Technologies Corporation formerly Applied Biosystmes, one of the biggest biotech company in US. Previously, she was a managing patent attorney at Celera Genomics, the first company sequenced human genome. Dr. Sun-Hoffman is admitted to the Maryland Bar and registered to practice before the U.S. Patent and Trademark Office.